AVROBIO, Inc. AVRO
Set alert
1.40 +1.40 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 5.24M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -8.24
- Beta
- 1.22
- Short ratio
- 0.70
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 16.17
- 200-d avg
- 16.46
- 1y target
- 2.00
2Y chart
Events in this range
- Dec 7, 2022Rating: BTIG · Neutral → Buy
- Mar 23, 2023Rating: Mizuho · — → Buy
- Mar 23, 2023Rating: Needham · — → Buy
- May 11, 2023Earnings: —; estimate -0.56; surprise —%
- Jul 11, 2023Downgrade: Wedbush · Outperform → Neutral
- Jul 12, 2023Rating: Wells Fargo · Overweight → Overweight
- Aug 10, 2023Earnings: —; estimate 1.35; surprise —%
- Nov 9, 2023Earnings: —; estimate -0.23; surprise —%
- Mar 14, 2024Earnings: —; estimate 0; surprise —%
- May 9, 2024Earnings: —; estimate 0; surprise —%
Signals (88)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Jun 11, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 7, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 6, 2024 | 2 years ago |
| RSI: Overbought | May 24, 2024 | 2 years ago |
| SMA: Bullish | May 22, 2024 | 2 years ago |
| SMA: Bullish | May 13, 2024 | 2 years ago |
| MACD: Buy Signal | May 2, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 16, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 11, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 10, 2024 | 2 years ago |
| SMA: Bearish | Apr 5, 2024 | 2 years ago |
| SMA: Bullish | Apr 3, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 1, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 13, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 7, 2024 | 2 years ago |
| SMA: Bearish | Jan 30, 2024 | 2 years ago |
| SMA: Bearish | Jan 30, 2024 | 2 years ago |
| RSI: Oversold | Jan 30, 2024 | 2 years ago |
| SMA: Bullish | Jan 26, 2024 | 2 years ago |
| SMA: Bearish | Jan 16, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 16, 2024 | 2 years ago |
| SMA: Bullish | Jan 2, 2024 | 2 years ago |
| SMA: Bearish | Dec 29, 2023 | 2 years ago |
| SMA: Bullish | Dec 27, 2023 | 2 years ago |
| MACD: Buy Signal | Dec 1, 2023 | 2 years ago |
| SMA: Bullish | Nov 30, 2023 | 2 years ago |
| SMA: Bearish | Nov 20, 2023 | 2 years ago |
| SMA: Bullish | Nov 17, 2023 | 2 years ago |
| SMA: Bearish | Nov 16, 2023 | 2 years ago |
| RSI: Oversold | Nov 10, 2023 | 2 years ago |
| SMA: Bearish | Nov 6, 2023 | 2 years ago |
| MACD: Sell Signal | Nov 6, 2023 | 2 years ago |
| MACD: Buy Signal | Nov 2, 2023 | 3 years ago |
| SMA: Bullish | Oct 31, 2023 | 3 years ago |
| SMA: Bearish | Oct 23, 2023 | 3 years ago |
| MACD: Sell Signal | Oct 20, 2023 | 3 years ago |
| MACD: Buy Signal | Oct 9, 2023 | 3 years ago |
| SMA: Bullish | Oct 6, 2023 | 3 years ago |
| SMA: Bearish | Oct 2, 2023 | 3 years ago |
| SMA: Bearish | Sep 22, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 12, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 7, 2023 | 3 years ago |
| RSI: Overbought | Sep 6, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 3, 2023 | 3 years ago |
| RSI: Overbought | Jul 28, 2023 | 3 years ago |
| RSI: Overbought | Jul 26, 2023 | 3 years ago |
| RSI: Overbought | Jul 20, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 12, 2023 | 3 years ago |
| RSI: Overbought | Jul 12, 2023 | 3 years ago |
| SMA: Bullish | Jun 30, 2023 | 3 years ago |
| SMA: Bullish | Jun 30, 2023 | 3 years ago |
| SMA: Bearish | Jun 23, 2023 | 3 years ago |
| SMA: Bearish | Jun 23, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 14, 2023 | 3 years ago |
| SMA: Bullish | May 22, 2023 | 3 years ago |
| SMA: Bullish | May 22, 2023 | 3 years ago |
| RSI: Overbought | May 22, 2023 | 3 years ago |
| MACD: Buy Signal | May 18, 2023 | 3 years ago |
| MACD: Sell Signal | May 2, 2023 | 3 years ago |
| SMA: Bearish | May 1, 2023 | 3 years ago |
| SMA: Bullish | Apr 28, 2023 | 3 years ago |
| SMA: Bearish | Apr 24, 2023 | 3 years ago |
| SMA: Bullish | Apr 21, 2023 | 3 years ago |
| SMA: Bearish | Apr 17, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 14, 2023 | 3 years ago |
| SMA: Bullish | Apr 13, 2023 | 3 years ago |
| SMA: Bearish | Apr 12, 2023 | 3 years ago |
| SMA: Bullish | Apr 11, 2023 | 3 years ago |
| SMA: Bearish | Apr 10, 2023 | 3 years ago |
| SMA: Bullish | Apr 6, 2023 | 3 years ago |
| SMA: Bearish | Mar 23, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 23, 2023 | 3 years ago |
| RSI: Overbought | Feb 16, 2023 | 3 years ago |
| MACD: Buy Signal | Feb 8, 2023 | 3 years ago |
| RSI: Overbought | Feb 8, 2023 | 3 years ago |
| MACD: Sell Signal | Feb 7, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 30, 2023 | 3 years ago |
| MACD: Sell Signal | Jan 27, 2023 | 3 years ago |
| MACD: Buy Signal | Jan 5, 2023 | 3 years ago |
| SMA: Bullish | Jan 3, 2023 | 3 years ago |
| SMA: Bearish | Dec 27, 2022 | 3 years ago |
| MACD: Sell Signal | Dec 7, 2022 | 3 years ago |
| RSI: Overbought | Nov 22, 2022 | 3 years ago |
| SMA: Bullish | Nov 11, 2022 | 3 years ago |
| RSI: Oversold | Oct 10, 2022 | 4 years ago |
| MACD: Buy Signal | Oct 7, 2022 | 4 years ago |
| RSI: Oversold | Sep 19, 2022 | 4 years ago |
| MACD: Sell Signal | Aug 23, 2022 | 4 years ago |
Key statistics
- Market cap
- 5.24M
- Enterprise value
- -27.41M
- Trailing P/E
- 0.17
- Forward P/E
- -8.24
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.06
- EPS (TTM)
- 8.28
- Beta
- 1.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -30.75M
- Total cash
- 90.48M
- Total debt
- 224.00K
- Return on equity
- 42.73%
- Shares outstanding
- 3.74M
- Short % of float
- 0.45%
- 50-day average
- 16.17
- 200-day average
- 16.46
Analyst view
Consensus: hold
Hold
Price target (mean) 2.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.08.
Financials — quick view
AVRO Revenue — quarterly 0
AVRO Net income — quarterly -6.81M
AVRO EPS — quarterly -0.15
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 14, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -0.23 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 1.35 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | -0.56 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 12, 2023 | Wells Fargo | main | Overweight | Overweight |
| Jul 11, 2023 | Wedbush | down | Outperform | Neutral |
| Mar 23, 2023 | Mizuho | main | — | Buy |
| Mar 23, 2023 | Needham | reit | — | Buy |
| Dec 7, 2022 | BTIG | up | Neutral | Buy |
| May 16, 2022 | Needham | main | — | Buy |
About AVROBIO, Inc.
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- avrobio.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on AVRO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ATLAS VENTURE FUND LP | Director | Purchase | Jul 18, 2019 | 0 |
| AVRUCH STEVEN N. J.D. | Officer | Conversion of Exercise of derivative security | Jan 31, 2024 | 22,022 |
| DONENBERG PHILLIP BRIAN | Director | Purchase | Feb 16, 2021 | 2,000 |
| GOLIPOUR AZADEH | Chief Technology Officer | Conversion of Exercise of derivative security | Jan 31, 2024 | 55,872 |
| LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 13, 2024 | 0 |
| MACKAY GEOFFREY | Chief Executive Officer | Conversion of Exercise of derivative security | Jan 23, 2023 | 778,343 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 10.20% | 4,541,381 | 4.31M | Jun 29, 2023 |
| Tang Capital Management, LLC | 6.07% | 2,705,000 | 2.57M | Jun 29, 2023 |
| GMT Capital Corp | 5.42% | 2,412,015 | 2.29M | Jun 29, 2023 |
| Acadian Asset Management. LLC | 3.98% | 1,770,147 | 1.68M | Jun 29, 2023 |
| Vanguard Group Inc | 2.65% | 1,181,134 | 1.12M | Jun 29, 2023 |
| Morgan Stanley | 2.36% | 1,049,270 | 996.91K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.42% | 630,579 | 599.11K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 1.21% | 537,481 | 510.66K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.50% | 223,158 | 245.47K | May 30, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.22% | 96,000 | 91.21K | Jun 29, 2023 |
| Fidelity Total Market Index Fund | 0.11% | 47,959 | 52.75K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.09% | 42,141 | 46.35K | May 30, 2023 |